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Objective: To examine whether toxaemia of pregnancy is associated with an increased risk of mortality, in particular premature death.
Methods: A cohort nested within the Royal College of General Practitioners’ Oral Contraception Study focusing on women who never used oral contraceptives. A total of 2865 parous women with a history of toxaemia of pregnancy were compared with 11460 parous women without such a history. Adjusted hazards ratios and 95% confidence intervals were calculated for death from all causes, vascular disease and cancer. Risk of premature death before the age of 65 years was compared between the two groups.
Results: Women with a history of toxaemia had a significant increased risk of death from any cause (adjusted HR 1.20, 95% CI 1.04-1.39) and from vascular disease (adjusted HR 1.38, 95% CI 1.05-1.82). Women with a history of toxaemia who did not subsequently develop hypertension or vascular disease had significantly increased risks of all-cause and vascular mortality. These risks were not found among women who developed these conditions. Toxaemia of pregnancy was not associated with premature death.
Conclusion:
Toxaemia of pregnancy was associated with increased mortality but not premature death. 
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Pre-eclampsia affects 2-8% of pregnancies1 and is responsible for over 30% of severe obstetric morbidity episodes.2 Research suggests that women who experience pre-eclampsia have an increased risk of a variety of vascular outcomes later in life, including hypertension;3-5 myocardial infarction;6-8 ischaemic heart disease;4, 9-12 stroke5, 13, 14 and venous thromboembolism.4, 15, 16 Many studies have looked at non-fatal outcomes. Some have assessed the possible impact of pre-eclampsia on future mortality, 5, 9-11, 13, 17, 18 although only one investigated premature death; finding an important adverse effect.11 Furthermore, most mortality studies have involved record linkage,9-11, 17 with limited information about possible confounders. Given the common occurrence of both pre-eclampsia and cardiovascular disease in many countries, it is important to determine whether pre-eclampsia is associated with premature mortality. 

We used data from a large cohort study to investigate whether women with a history of toxaemia of pregnancy (the term used previously for what is now called pre-eclampsia) have an increased mortality risk compared with women without this history, and if so whether they are more likely to die prematurely. 

Methods 
Royal College of General Practitioners’ Oral Contraception Study (OCS)
The aim of the OCS is to determine the long-term health effects of oral contraceptives. The study began in 1968 when 1400 general practitioners (GPs) throughout the United Kingdom (UK) recruited 23,000 women who were using oral contraceptives and a similar number of age-matched women who had never done so.19 The mean age of the women at recruitment was 29 years, most (98%) were Caucasian and all were married/living as married. Information collected at baseline included social class (as determined by husband’s occupation),20 number of cigarettes smoked daily, details of any previous use of oral contraceptives, parity and significant medical history (notified by GPs ticking a series of boxes for different conditions, including toxaemia of pregnancy). At six-monthly intervals thereafter the GPs provided details of any: hormonal preparations prescribed, pregnancies, surgery, new episodes of illness and deaths.

During the mid-1970s, 75% of the cohort was “flagged” at the National Health Service (NHS) Central Registries for notification of future death and cancer registrations. The other women could not be flagged because they/their GP had already left the study. GP observation ceased in 1996 but death and cancer registrations continue to be notified.

Although the OCS was established before the introduction of Research Ethics Committees in the UK, the study was conducted in a manner consistent with the Declaration of Helsinki. Subject confidentiality was of paramount importance. Thus, all reports and  correspondence between participating GPs and the study co-ordinating unit used a unique study number, the key to which only the GPs knew. Data from the NHS Central Registries also uses this study number, thereby avoiding the need for the study to hold identifying information. 

Nested cohort
We identified all women who were recruited to the OCS as parous never users of oral contraceptives and who had toxaemia of pregnancy recorded at recruitment as part of their significant medical history (see Figure 1). We focused on never users since combined oral contraceptives can raise blood pressure in some women21 and we did not want to confuse any, usually temporary, effects of  oral contraceptive-related blood pressure rises from the effects of toxaemia. For each (index) woman with a history of toxaemia, (to increase statistical power) we randomly identified four “non-exposed” women i.e. without toxaemia, who at the recruitment date of the index woman: (i) were of similar age (date of birth within five years), (ii) under study follow-up and (iii) parous. As we did not have details of when the women experienced their toxaemia of pregnancy, we used recruitment date to the OCS as a proxy date. Each non-exposed woman was assigned a “pseudo-diagnosis” date, of the same month and year as the date of recruitment (diagnosis date) of the matched index exposed woman.





Data were analysed using SPSS for Windows version 14.0.23 Baseline differences in the characteristics of women with a history of toxaemia and those without were compared using the Chi-square test for categorical variables and independent two-sample t-tests for continuous Normally distributed variables. Continuous variables were then transformed into categorical variables (age: younger than age 30, 30 years or older; parity: 1, 2, 3 or more; number of cigarettes per day at recruitment: none, 1-14, 15 or more). Social class was categorised as non-manual (classes I-IIIa and husbands recorded as students or commissioned armed forces) or manual (classes IIIb-V and husbands recorded as non-commissioned armed forces). We compared duration of follow-up between the groups using the Mann-Whitney test for non-Normally distributed data. 

Using Kaplan-Meier survival curves and the logrank test, we compared the probability of survival among women who had a history of toxaemia with those who had not experienced this condition, in terms of death from any cause, vascular disease, cancer and other (non-vascular or malignant) causes. We examined Kaplan-Meier survival curves for each of the potential confounding variables (e.g. social class) and survival time to check for deviation from the proportional hazards assumption. Women were excluded from the survival analyses if they had a history of: hypertension; ischaemic heart; cerebrovascular; peripheral vascular; thromboembolic; acquired valvular heart or congenital heart disease; diabetes mellitus or malignancy before or on the date of toxaemia diagnosis/pseudo-diagnosis.

The relationship between history of toxaemia of pregnancy and survival time after adjustment for possible confounding was examined using forward conditional stepwise Cox regression. Along with toxaemia of pregnancy, age, social class, smoking and parity were free to enter the model in a stepwise manner if they had a p-value of 0.05 (and removed if p0.10). The effect of interaction terms between each potential confounder and exposure status on the final models was assessed using the likelihood ratio test.

Women were censored from the survival analyses when: (i) they began using oral contraceptives; (ii) they left GP observation without being “flagged” at the NHS Central Registries; (iii) they left GP observation whilst “flagged”, but before the age of 38 years (since we did not know whether the women subsequently started to use oral contraceptives - we assumed that older women were unlikely to have done so since 91% of women who used oral contraceptives did so before age 38); (iv) a non-exposed woman had a new pregnancy affected by toxaemia; or when (v) during the cause-specific mortality analyses women died from a cause other than the one under consideration.

To explore the hypothesis that the mechanism for any increased mortality risk might be mediated by hypertension or vascular disease in mid-life, we repeated our main analyses stratified by whether women had a known history of hypertension or vascular disease whilst under GP follow-up i.e. were reported as having hypertension or vascular disease between the date of their diagnosis/pseudo diagnosis and the date that GP observation ceased for each woman.

 To investigate whether women with a history of toxaemia of pregnancy were more likely to die prematurely compared with parous women without a history of toxaemia, we repeated the Kaplan-Meier and Cox regression analyses using premature death (age<65 years) as the endpoint. 

Results
We compared 2865 parous women with a history of toxaemia of pregnancy at recruitment to the OCS with 11460 parous non-exposed women. The women with a history of toxaemia had a mean age of 30.5 years (standard deviation, SD=6.3) at recruitment to the study compared with a mean age of 30.2 years (SD=6.3), p=0.022 in the no toxaemia group. Although this difference was statistically significant, (because of the large number of women in the analysis) the clinical relevance of the difference is likely to be very small. The toxaemia group had a significantly higher mean parity than the no toxaemia group (2.2, SD=1.2 vs. 2.0, SD=1.1, p<0.001). Significantly higher proportions of exposed women were non-smokers and had a history of hypertensive disease and diabetes mellitus than those without toxaemia (Table 1). After excluding women who had a history of chronic disease at recruitment to the OCS, the univariate relationships shown in Table 1 remained unchanged (data not shown). 

Duration of follow-up was significantly longer (p<0.001) among women without toxaemia (median=104.5 months, interquartile range 28.5-441.3) than among women with toxaemia (median=87.0 months, interquartile range 24.8-440.3). By the end of follow-up 1172 women had died, mainly from vascular disease or cancer (Table 2). 

The Kaplan-Meier plot for all cause mortality showed that the cumulative survival probability for women with a history of toxaemia was significantly lower than for women without this history (logrank χ2 =7.13, 1 df, p=0.008; Figure 2). Similarly, when examining death from vascular disease, the cumulative survival probability was significantly lower among women exposed to toxaemia of pregnancy (logrank χ2 =7.70, 1 df, p=0.006; Figure 3). There was no difference in survival between the toxaemia and the no toxaemia groups for death from cancer or from other causes. For all outcomes, visual inspection of the Kaplan-Meier plots for each of the potential confounding factors and survival time revealed no apparent deviation from the proportional hazards assumption (data not shown).

After adjustment for confounding, women with a history of toxaemia had a statistically significant increased risk of death from any cause (adjusted hazard ratio, HR=1.20, 95% confidence interval (CI) 1.04-1.39) and from vascular disease (adjusted HR=1.38, 95% CI 1.05-1.82), compared with women without this history (Table 3). Women exposed to toxaemia also experienced a non-significant increased risk of death from cancer and from causes other than vascular disease or cancer.

The nested cohort was stratified by whether or not the women were reported to have hypertension during GP follow-up. Among those not reported to have developed hypertension, women with a history of toxaemia had a significantly greater risk of death from all, and vascular, causes than women without toxaemia (Table 4). In contrast, among women with a history of hypertension, the toxaemia of pregnancy group had adjusted hazard ratios close to unity for both outcomes. Similar patterns were found when the nested cohort was stratified by whether or not the women were reported to have developed vascular disease during follow-up. 





Women with a history of toxaemia of pregnancy had a significant 20% increased risk of subsequent death from any cause and a 38% increased risk of death from vascular causes, compared with women without such a history. These risks were seen mainly in women who were not diagnosed with hypertension or vascular disease during follow-up. History of toxaemia of pregnancy however was not significantly associated with premature death before the age of 65 years.

Our cohort was followed for up to 36 years, allowing us to examine possible long-term mortality risks associated with having by an average age of 30 years at least one episode of toxaemia of pregnancy. In the OCS, it is unlikely that the GPs’ diagnosis of hypertension, vascular disease or cause of death was biased by their knowledge of whether a woman had a history of toxaemia, since early research concluded that toxaemia did not cause chronic vascular disease or subsequent hypertension.24

Smoking remained a significant variable in all of the mortality models. That said, smoking status was based on information collected at recruitment to the OCS and it is likely that the smoking habits of the women will have changed over time. In a subset of the cohort surveyed in the mid-1990s, substantially more of the middle-aged women had stopped rather than started smoking.25 The effects of smoking, therefore, are likely to be underestimated. Many other studies, particularly those using hospital maternity records or birth registries9-12, 16-18 have been unable to adjust for the effects of smoking. 

We excluded women who had pre-existing medical conditions at baseline because these conditions may have been  associated with an increased risk of mortality and because we did not know whether these events occurred before, during or after pregnancy. The number of women with particular histories (shown in Table 1) was usually small. It is possible that we excluded some women who developed a mortality-relevant event (e.g. hypertension) after pregnancy but before recruitment to the OCS. Exclusion of these women will tend to have underestimated the effects of toxaemia of pregnancy if the mortality risks associated with toxaemia operate through this mechanism. Similarly, our risk estimates will have been underestimated if some women died very soon after a toxaemic pregnancy, and so did not survive to be recruited to the OCS in the first place. The number of such events is likely to be small, so the effects shall be modest. We avoided possible contaminant effects of oral contraception on blood pressure by censoring women if they started using those products. 

In contrast, we did not have details about: which, or how many, pregnancies were affected by the toxaemia, the stage of pregnancy when toxaemia occurred, the severity of the condition, the criteria used to make the diagnosis or the treatment used. It is likely that women reported to have toxaemia experienced a variety of hypertensive problems associated with pregnancy. 

By the end of follow-up, just over one third of our toxaemia cohort remained in the study flagged (i.e. known to still be alive) at the NHS Central Registries. The main OCS incurred a large loss to follow-up, mainly because women left their GP practice before the flagging procedure happened. We have shown however that the large loss to follow-up has not biased mortality rates.26 

Similar to our results, during four decades of follow-up, Funai and colleagues18 found an increased risk of death among women with a history of pre-eclampsia who were subsequently normotensive. Other studies of UK women with a history of pre-eclampsia5, 10 have found an increased risk of death from any causes (10% and 17% respectively), which is of a similar magnitude to the 20% increased risk that we found. Research based on women in Iceland9 and Norway17 also produced similar risks. Of the various mortality outcomes investigated, we found that the greatest risk associated with a history of toxaemia of pregnancy was with respect to death from vascular disease. This was similar to a cohort study of women in Jerusalem with a history of pre-eclampsia (death from cardiovascular disease RR=3.07, 95% CI 2.18-4.34).18

In order to have sufficient power, we combined deaths from ischaemic heart disease, cerebrovascular disease, and other forms of heart and vascular disease together, into death from vascular disease. This means that we were unable to determine the risk of death from specific vascular causes. Smith and colleagues used routine hospital discharge and mortality data in Scotland, and found that pre-eclampsia during first pregnancy was associated with a non-significant increased risk of death from ischaemic heart disease (adjusted HR=1.7, 95% CI 0.9-3.3).10 Another investigation found that women with a history of pre-eclampsia had an adjusted incident rate ratio of dying from ischaemic heart disease of 1.95, 95% CI 0.90-4.21.5 However, in both studies relatively few women died, which may explain the absence of statistically significant findings.

Our results provide some support for other research suggesting an increased risk of cancer death, 11, 18 but contradicts another study which suggested that pre-eclamptic women who deliver pre-term have a reduced risk of dying from cancer compared with women without pre-eclampsia who deliver at term.17

Our results do not support the hypothesis that women with a history of toxaemia of pregnancy have an increased risk of dying at a younger age than women without a history of toxaemia. A case-control study of 325 women with hypertensive pregnancies who delivered between 1931 and 1947 in Iceland, found that survival was poorer as a result of cardiovascular deaths among cases than controls in women who were aged 25-34 years at the time of the index pregnancy (median survival time among cases 50 years, 95% CI 48-52 vs. 53 years, 95% CI 51-55 among controls) or aged 35 years and older at the time of the affected pregnancy (median survival time among cases 36 years, 95% CI 31-41 vs. 45 years, 95% CI 42-48 among controls).11 This poorer survival was not found among women aged 15-24 years at the time of their pregnancy.

We tried to examine whether the mortality risk from all or vascular causes was mediated through hypertension or vascular disease in mid-life in women with a history of toxaemia. The history of hypertension or vascular disease only related to illness reported during GP follow-up. Some women regarded as having no such history could have developed these conditions after leaving GP observation. To have affected our results however, hypertension or vascular disease developing later in life would have to have a stronger association with mortality risk than similar events diagnosed at a younger age. Our study lacked information about how any hypertension or vascular disease was managed. We cannot exclude therefore the possibility of better/more active treatment among the hypertension or vascular disease group contributing to our findings.

The pattern of risk seen in our stratified analyses (i.e. increased risk seen in toxaemia women without hypertension or vascular disease, but no increase seen in women with these problems) might be because the mortality risk imposed by the development of hypertension or vascular disease in mid-life is more powerful than that associated with toxaemia of pregnancy itself. Relative risk reduction is the amount by which a person’s risk of disease is reduced by the elimination of an exposure.27 So, for vascular death in Table 4, the relative risk reduction attributable to toxaemia of pregnancy is 54% compared with a relative risk reduction attributable to hypertension of 100%. Thus a woman who has a history of toxaemia has a significant but modest increased risk of vascular mortality which becomes obscured if hypertension develops. In all our models we adjusted for smoking, therefore none of the patterns observed were due to differences in the prevalence of smoking among women with/without toxaemia.

The general pattern of increased risk of mortality, especially from vascular causes, confirms other research.5, 9-12, 17-18 The problem of identifying when the increased cardiovascular risk first emerges remains unresolved. One study has suggested that there may be a latent period of 20 years after a pre-eclamptic pregnancy before an excess risk appears.18 Our Kaplan-Meier plots are compatible with such a prolonged latent period. The mechanism by which such effects occur is unclear - suggested hypotheses are that pre-eclampsia and cardiovascular disease might have a similar pathogenesis or alternatively, that pre-eclampsia might cause long-term metabolic and vascular abnormalities that would increase risk of cardiovascular disease later in life.28 Our work reinforces the need to discover the mechanisms by which the long-term effects of toxaemia/pre-eclampsia are produced, to inform the development of appropriate interventions to prevent the onset of these complications. 

What are the practical implications of research about the long-term sequelae of pre-eclampsia for clinical practice? In the absence of clinical indicators of high cardiovascular risk (i.e. a previous cardiovascular event, history of diabetes or familial hypercholesterolaemia), some guidelines suggest that all adults aged 40 and older should have their cardiovascular risk (including a blood pressure check) assessed every five years.29 As a minimum, women with a history of pre-eclampsia in pregnancy should be informed that they may have an increased risk of vascular disease later in life, and so are strongly encouraged to participate in any screening programme. However, this advice needs to be conveyed sensitively in order not to generate unnecessary anxiety whilst not underplaying the importance of the message.  
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Figure 1. Flowchart of toxaemia of pregnancy nested cohort study
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* Social class information missing for 34 women and smoking information missing for 47 women




Cause of death (ICD8 code)	All	n	(%)	n	(%)
Vascular disease (390-8, 410-3, 420-9, 	321	88	(32.5)	233	(25.9)
430-8, 440-4, 450-3,)					
					










Lymphatic & haematopoietic tissues (200-9)	41	7	(2.6)	34	(3.8)
Other cancers (140-9, 152, 157-61, 163, 170-3,	141	36	(13.3)	105	(11.7)
184, 188-9, 190-9)					
					
Diseases of the respiratory system (460-6, 470-4,	125	26	(9.6)	99	(11.0)
480-6, 490-3, 500-8, 510-9)					









Table 3. Long term risk of death among women with a history of toxaemia of pregnancy (TOP) compared with women without a record of this condition at recruitment to the RCGP OCS. Data from 13,718 women modelled including 1061 who died during follow-up*

		n	Unadjusted	Adjusted	
Cause of death	TOP	died: alive	HR, 95% CI	HR, 95% CI	Variables in model
All causes	No	828:4290	1.00	1.00	Age group









	Yes	102:964	1.14, 0.92-1.42	1.14, 0.91-1.41	No. of cigarettes/day
					
Other causes	No	231:4290	1.00	1.00	Age group
(except vascular	Yes	60:964	1.13, 0.85-1.50	1.16, 0.87-1.54	Social class
disease or cancer)					No. of cigarettes/day
				Interaction: TOP*No. of cigarettes/day










	TOP	died: alive	Adjusted HR, 95% CI	Variables in model	died: alive	Adjusted HR, 95% CI	Variables in model
No hypertension	No	670: 3677	1.00	Age group	156:3677	1.00	Age group
	Yes	160: 697	1.21, 1.01-1.44	Social class	47:697	1.44, 1.03-2.02	Social class
				No. of cigarettes/day			No. of cigarettes/day
							Parity 
							
Hypertension 	No	158:613	1.00	Age group	55: 613	1.00	Age group
	Yes 	73:267	1.06, 0.80-1.40	No. of cigarettes/day	24: 267	0.97, 0.59-1.57	No. of cigarettes/day
							
No vascular disease	No	719:4057	1.00	Age group	164:4057	1.00	Age group
	Yes 	200:886	1.22, 1.04-1.43	Social class	54:886	1.37, 1.00-1.88	Social class
				No. of cigarettes/day			No. of cigarettes/day
							
Vascular disease	No	109:233	1.00	No. of cigarettes/day	47:233	1.00	No. of cigarettes/day
	Yes 	33:78	0.93, 0.63-1.37		17:78	1.19, 0.64-1.93	




Table 5. Risk of premature death among women with a history of toxaemia of pregnancy compared with women without a record of this condition at recruitment to the OCS. Data from 13,718 women modelled including 580 who died aged<65 years during follow-up

	n*	Unadjusted	Adjusted























*HR, hazard ratio. Numbers included in the final model may be lower due to missing covariate information for some women. Adjustments made for all of the variables included in the final model. Excluded from the analysis were 607 women with a previous history of hypertensive disease; ischaemic heart disease; cerebrovascular disease; peripheral vascular disease; thromboembolic disease; acquired valvular heart disease; congenital heart disease; diabetes mellitus or malignancy.






Construction of toxaemia of pregnancy nested cohort

9471 not included in nested cohort - nulliparous or did not meet inclusion criteria

11,460 parous women with no toxaemia of pregnancy 









607 excluded from survival analysis 
due to medical history prior to recruitment

Women were censored from survival analysis if they:
	Began to use oral contraceptives, n=2591
	Left the study before being flagged at NHS registries, n=2482
	Left the study flagged but aged <38yrs (at risk of OC use), n=2282
	Were in the no toxaemia of pregnancy group and had a new pregnancy affected by toxaemia, n=48









¾ of cohort remaining under follow-up flagged at NHS Central Registries for notification of deaths & cancers
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